A made-in-India version of a targeted breast-cancer drug is holding up in real-world hospital data

Doctors across India have pooled real-world results for UJVIRA, a biosimilar — a close, lower-cost copy — of trastuzumab emtansine, a targeted medicine for HER2-positive breast cancer, a fast-growing form of the disease. The multicentre analysis, published in the peer-reviewed journal Breast Cancer Research and Treatment, tracked patients with both early and metastatic disease treated in everyday hospital practice, outside the tidy conditions of a trial, and found the biosimilar performed as a working treatment option. Evidence like this is what lets hospitals adopt more affordable versions with confidence — the unglamorous step between a drug existing and a patient actually receiving it.

SDG 3 · Good health and well-being — Mechanism: tech innovation